Nippon Kayaku's NK105 fails breast cancer Phase III

NK105 micellar paclitaxel from Nippon Kayaku Co. Ltd. (Tokyo:4272) missed the primary

Read the full 128 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE